Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

625 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trial.
Beck LA, Bieber T, Weidinger S, Tauber M, Saeki H, Irvine AD, Eichenfield LF, Werfel T, Arlert P, Jiang L, Røpke M, Paller AS. Beck LA, et al. Among authors: werfel t. J Am Acad Dermatol. 2023 Apr;88(4):816-823. doi: 10.1016/j.jaad.2022.11.047. Epub 2022 Dec 5. J Am Acad Dermatol. 2023. PMID: 36473633 Free article. Clinical Trial.
Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate-to-severe atopic dermatitis.
Hartmann J, Moitinho-Silva L, Sander N, Harder I, Häsler R, Rodriguez E, Haufe E, Kleinheinz A, Abraham S, Heratizadeh A, Weisshaar E, Schäkel K, Handrick C, Augustin M, Wollenberg A, Staubach-Renz P, Ertner K, Sticherling M, Schwarz B, Quist S, Wiemers F, Schenck F, Wildberger J, Tittmann L, Lieb W, Schmitt J, Werfel T, Weidinger S; TREATgermany Study Group. Hartmann J, et al. Among authors: werfel t. Allergy. 2023 Aug;78(8):2290-2300. doi: 10.1111/all.15742. Epub 2023 Apr 18. Allergy. 2023. PMID: 37032440
High recurrence rate of eczema herpeticum in moderate/severe atopic dermatitis -TREATgermany registry analysis.
Traidl S, Heinrich L, Siegels D, Rösner L, Haufe E, Harder I, Abraham S, Ertner K, Kleinheinz A, Schäkel K, Wollenberg A, Effendy I, Quist S, Asmussen A, Wildberger J, Weisshaar E, Wiemers F, Brücher JJ, Weidinger S, Schmitt J, Werfel T; TREATgermany Study Group. Traidl S, et al. Among authors: werfel t. J Dtsch Dermatol Ges. 2023 Dec;21(12):1490-1498. doi: 10.1111/ddg.15205. Epub 2023 Oct 9. J Dtsch Dermatol Ges. 2023. PMID: 37814394
Itching and treatments in atopic dermatitis (AD): results from the German AD registry TREATgermany.
Weisshaar E, Bentz P, Haufe E, Heinrich L, Apfelbacher C, Heratizadeh A, Abraham S, Harder I, Kleinheinz A, Wollenberg A, Schäkel K, Wiemers F, Ertner K, Augustin M, Wildberger J, von Kiedrowski R, Worm M, Zink A, Effendy I, Asmussen A, Pawlak M, Sticherling M, Hilgers M, Handrick C, Quist S, Schwarz B, Bell M, Staubach-Renz P, Hong-Weldemann SH, Homey B, Bruecher J, Weidinger S, Werfel T, Schmitt J; TREATgermany study group. Weisshaar E, et al. Among authors: werfel t. Br J Dermatol. 2023 Feb 22;188(3):430-432. doi: 10.1093/bjd/ljac070. Br J Dermatol. 2023. PMID: 36763757 No abstract available.
Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7.
Silverberg JI, Simpson EL, Thyssen JP, Werfel T, Cardillo TE, Colvin S, Pierce E, Chen YF, Chen S, Eichenfield L. Silverberg JI, et al. Among authors: werfel t. J Eur Acad Dermatol Venereol. 2023 May;37(5):1036-1045. doi: 10.1111/jdv.18816. Epub 2023 Jan 20. J Eur Acad Dermatol Venereol. 2023. PMID: 36514996 Clinical Trial.
Itching in Atopic Dermatitis: Patient- and Physician-reported Outcomes in the German Atopic Dermatitis Registry TREATgermany.
Weisshaar E, Bentz P, Apfelbacher C, Haufe E, Heinrich L, Heratizadeh A, Abraham S, Harder I, Kleinheinz A, Wollenberg A, Schäkel K, Wiemers F, Ertner J, Augustin M, Wildberger J, Von Kiedrowski R, Worm M, Zink A, Effendy I, Asmussen A, Pawlak M, Sticherling M, Hilgers M, Handrick C, Quist S, Schwarz B, Bell M, Staubach-Renz P, Hong-Weldemann SH, Homey B, Brücher JJ, Weidinger S, Werfel T, Schmitt J; TREATgermany study group. Weisshaar E, et al. Among authors: werfel t. Acta Derm Venereol. 2023 Jan 23;103:adv00854. doi: 10.2340/actadv.v103.4426. Acta Derm Venereol. 2023. PMID: 36688701 Free PMC article.
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
Reich K, Silverberg JI, Papp KA, Deleuran M, Katoh N, Strober B, Beck LA, de Bruin-Weller M, Werfel T, Zhang F, Biswas P, DiBonaventura MD, Chan G, Johnson S, Farooqui SA, Kerkmann U, Clibborn C. Reich K, et al. Among authors: werfel t. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):2056-2066. doi: 10.1111/jdv.19280. Epub 2023 Jul 11. J Eur Acad Dermatol Venereol. 2023. PMID: 37335885
625 results